FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243058101> ?p ?o ?g. }

• W4243058101 endingPage "0199" @default.
• W4243058101 startingPage "0190" @default.
• W4243058101 abstract "Overproduction of catecholamines (dopamine [DA], norepinephrine [NE]) and their metabolites (homovanillic [HVA] and vanillylmandelic [VMA] acids) characterizes neuroblastoma (NB). In previous studies, increased urinary DA/NE, and DA/VMA ratios have been associated with poor prognosis, whereas low DA/NE ratios have been associated with longer disease-free survival. Higher urinary VMA, HVA, and NE levels have been found in association with low MYCN amplification, in contrast to cases with high MYCN amplification in which normal levels have been found. It is then believed that an “immature” catecholamine pattern indicates poor prognosis. We correlated urinary DA, NE, VMA, and HVA levels with age, clinical tumor stage, histological features (favorable [FH]/unfavorable [UH]) and MYCN status of 33 patients with NB. DA/VMA and DA/HVA ratios were also calculated. Wilcoxon rank sum and chi-squared tests were performed to determine statistical significance. Eighty-eight percent (15/17) of stage 3–4 cases had DA levels >2 times the upper limit of normal, but only 8% (1/12) of stage 1–2 cases had DA levels twice the upper limit of normal. In 61% (11/18) of stage 3–4 cases, the VMA level was >10 times the upper limit of normal, in contrast to stage 1–2 cases, in which only one patient (1/15) had a VMA level >10 times the upper limit of normal. Similar findings were obtained with urinary HVA and NE. Patients older than 12 months of age at diagnosis also had higher urinary levels of DA, VMA, HVA, and NE than those of patients younger than 12 months of age at diagnosis. Eighty-two percent (14/17) of stage 3–4 cases had DA/VMA ratios <0.78, with the other 18% (3/17) showing ratios between 1.4 and 8.82 (all stage 4 and >12 months of age). In contrast, all stage 1–2 cases (12) had ratios <1.4. All (12/12) non–MYCN-amplified cases had DA/VMA ratios <1.4 (0.06–0.84), while one MYCN-amplified case (1/3) had a ratio of 8.82; the other two MYCN-amplified cases had DA/VMA ratios of 0.09–0.11. Twenty-nine percent (2/7) of cases with UH had a DA/VMA ratio >1.4, but in all FH cases (14/14) the DA/VMA ratio was <1.4 (0.08–0.084). Similar to previous studies, we found that aggressive NB is associated with higher urinary levels of DA, VMA, HVA, and NE. We also confirmed the previous observation that there appears to be a subset of NB in which a possible blockade in DA metabolism is associated with poor prognostic features (>12 months, stage 4, UH, and MYCN amplification). A seemingly novel observation in our study is that all high DA/HVA and DA/VMA ratios were obtained in stage 4 tumors, suggesting an association between the inability to metabolize DA and the acquisition of metastatic potential. On the basis of our results, we would like to emphasize the importance of determining not only DA, HVA, and VMA urinary levels, to support the diagnosis of NB, but also DA/HVA and DA/VMA ratios as a rapid initial assessment of prognosis in these patients." @default.
• W4243058101 created "2022-05-12" @default.
• W4243058101 creator A5022134669 @default.
• W4243058101 creator A5090422201 @default.
• W4243058101 date "2002-03-01" @default.
• W4243058101 modified "2023-10-18" @default.
• W4243058101 title "Hormonal Activity May Predict Aggressive Behavior in Neuroblastoma" @default.
• W4243058101 doi "https://doi.org/10.1007/s10024-001-0145-8" @default.
• W4243058101 hasPublicationYear "2002" @default.
• W4243058101 type Work @default.
• W4243058101 citedByCount "0" @default.
• W4243058101 crossrefType "journal-article" @default.
• W4243058101 hasAuthorship W4243058101A5022134669 @default.
• W4243058101 hasAuthorship W4243058101A5090422201 @default.
• W4243058101 hasConcept C126322002 @default.
• W4243058101 hasConcept C126894567 @default.
• W4243058101 hasConcept C134018914 @default.
• W4243058101 hasConcept C146357865 @default.
• W4243058101 hasConcept C151730666 @default.
• W4243058101 hasConcept C170493617 @default.
• W4243058101 hasConcept C2775841634 @default.
• W4243058101 hasConcept C2775864247 @default.
• W4243058101 hasConcept C2776715637 @default.
• W4243058101 hasConcept C2779089960 @default.
• W4243058101 hasConcept C54355233 @default.
• W4243058101 hasConcept C71924100 @default.
• W4243058101 hasConcept C77411442 @default.
• W4243058101 hasConcept C81885089 @default.
• W4243058101 hasConcept C86803240 @default.
• W4243058101 hasConcept C90924648 @default.
• W4243058101 hasConceptScore W4243058101C126322002 @default.
• W4243058101 hasConceptScore W4243058101C126894567 @default.
• W4243058101 hasConceptScore W4243058101C134018914 @default.
• W4243058101 hasConceptScore W4243058101C146357865 @default.
• W4243058101 hasConceptScore W4243058101C151730666 @default.
• W4243058101 hasConceptScore W4243058101C170493617 @default.
• W4243058101 hasConceptScore W4243058101C2775841634 @default.
• W4243058101 hasConceptScore W4243058101C2775864247 @default.
• W4243058101 hasConceptScore W4243058101C2776715637 @default.
• W4243058101 hasConceptScore W4243058101C2779089960 @default.
• W4243058101 hasConceptScore W4243058101C54355233 @default.
• W4243058101 hasConceptScore W4243058101C71924100 @default.
• W4243058101 hasConceptScore W4243058101C77411442 @default.
• W4243058101 hasConceptScore W4243058101C81885089 @default.
• W4243058101 hasConceptScore W4243058101C86803240 @default.
• W4243058101 hasConceptScore W4243058101C90924648 @default.
• W4243058101 hasIssue "2" @default.
• W4243058101 hasLocation W42430581011 @default.
• W4243058101 hasOpenAccess W4243058101 @default.
• W4243058101 hasPrimaryLocation W42430581011 @default.
• W4243058101 hasRelatedWork W1558507600 @default.
• W4243058101 hasRelatedWork W1614570650 @default.
• W4243058101 hasRelatedWork W1970249090 @default.
• W4243058101 hasRelatedWork W1980638703 @default.
• W4243058101 hasRelatedWork W1998219236 @default.
• W4243058101 hasRelatedWork W2003701830 @default.
• W4243058101 hasRelatedWork W2029714004 @default.
• W4243058101 hasRelatedWork W2068404113 @default.
• W4243058101 hasRelatedWork W2401700681 @default.
• W4243058101 hasRelatedWork W2731868265 @default.
• W4243058101 hasVolume "5" @default.
• W4243058101 isParatext "false" @default.
• W4243058101 isRetracted "false" @default.
• W4243058101 workType "article" @default.